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The enzyme linked immunoassay that we assessed is
highly accurate in diagnosing childhood H pylori
infection. The use of a grey zone may lower its accuracy,
but the accuracy is satisfactory even with direct visual
reading of the microwells without use of a plate reader;
this makes it fairly cheap as a screening test (one deter›
mination cost is 22 euro (£14), half the average price of
the urea breath test) and practical for epidemiological
studies.
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Gastroenterology and Hepatology.
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wrote the article. AR and BR collected the data from each cen›
tre, analysed the faecal samples and did the statistical analysis.
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about the design of the study and approved the study proposal
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tre. GO will act as guarantor for the paper.
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Effect of hormone replacement therapy on the
pathological stage of breast cancer: population based,
cross sectional study
Sheila Stallard, Janet C Litherland, Carolyn M Cordiner, Hilary M Dobson, W David George,
Elizabeth A Mallon, David Hole
Hormone replacement therapy is being used increas›
ingly. Although it is known that the risk of developing
breast cancer is slightly increased with long term use,1
hormone replacement does not seem to adversely
affect mortality from breast cancer.2
Studies have suggested that users of hormone
replacement who get breast cancer develop tumours
with “favourable” pathological features compared with
non›users. One study included women who had been
detected at screening and women who had presented
with symptoms, with more screen detected women in
the study group (users) than in the controls
(non›users).2 Another study compared type of tumour
in users and non›users in a screen detected population
alone3 and showed that grade 1, node negative
tumours were more common in the users.
Women with breast cancer who have used
hormone replacement, however, may be more likely to
have a cancer that was missed at screening; we have
shown that women who develop such cancers (interval
cancers) within a year of screening are twice as likely to
have been using hormone replacement when they
were screened.4 We compared pathological features of
tumours in both screen detected and interval cancers
to assess whether previous use of hormone replace›
ment therapy improves prognosis among women who
develop breast cancer.
Patients, methods, and results
The study population comprised all 1130 women
aged 50›64 years who underwent routine breast
screening during May 1988 to December 1993 in the
area of Scotland covered by the West of Scotland
Breast Screening Unit and who either had a screen
detected cancer or developed an interval cancer. Data
on interval cancers were collected up to the end of
1996. Current use of hormone replacement (yes/no)
had been recorded by radiographers at the time of
screening and also at assessment for women with
screen detected cancers. The case notes of half the
women with interval cancers were reviewed to check
whether use of hormone replacement at the time of
presentation was the same as at their last screening.
Seventeen women were excluded because use of
hormone replacement was unknown, leaving 1113
patients for analysis.
Of the 815 women with screen detected cancers,
100 (12.3%) were using hormone replacement when
they were screened. Of the 298 women with interval
cancer, 66 (22.1%) were using hormone replacement;
use at diagnosis was the same as at their previous
screen. Of the total number of women studied,
therefore, 166 (14.9%) were using hormone replace›
ment at the time they developed breast cancer.
We found no difference in type, size, or grade of
tumour in users compared with non›users (table).
Twenty four per cent of users developed well differen›
tiated tumours (tubular, mucoid, and invasive ductal
grade 1 cancers) compared with 22% of non›users.
This equates to an odds ratio of 0.98 (95% confidence
interval 0.63 to 1.50). Seventy seven per cent of users
were node negative compared with 67% of non›users.
There was no difference in mean tumour size (mean
difference 0.25 mm (›2.02 mm to 2.53 mm)) in users
compared with non›users. No difference was seen in
the distribution of the Nottingham prognostic index5
between the two groups. Eight per cent of women
using hormone replacement developed ductal carci›
noma in situ compared with 15% of non›users. When
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screen detected cancers were analysed alone, no differ›
ences were found between the type, grade, size, or
nodal status in users compared with non›users.
Comment
Our results do not support the commonly held view
that women using hormone replacement therapy
develop tumours with favourable prognostic features.
Little information currently exists about the relation
between the development of ductal carcinoma in situ
and use of hormone replacement. Our numbers are
small, and further studies are needed. We show,
however, that women using hormone replacement do
not develop poorer prognosis tumours, and this is
reassuring to doctors prescribing hormone replace›
ment therapy.
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Screening Centre, Glasgow.
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Pathological features of breast cancer by use of hormone replacement therapy. Values are numbers (percentages) unless stated
otherwise
All cancers (n=1113) Screen detected cancers (n=815)
Users (n=166) Non›users (n=947) Users (n=100) Non›users (n=715)
Type and grade
Ductal carcinoma in situ 12 (7.9) 133 (14.9) 12 (12.5) 128 (18.3)
Invasive ductal cancer:
Grade 1* 36 (23.7) 198 (22.2) 23 (23.9) 175 (25.1)
Grade 2 52 (34.2) 252 (28.3) 34 (35.4) 201 (28.8)
Grade 3 19 (12.5) 105 (11.8) 7 (7.3) 48 (6.9)
Grade not known 22 (14.5) 133 (14.9) 14 (14.6) 98 (14.0)
Lobular 11 (7.2) 59 (6.6) 6 (6.3) 39 (5.6)
Other 0 11 (1.2) 0 9 (1.3)
Missing data 14 56 4 17
Significance ÷2=8.33, df=6, P=0.21 ÷2=4.26, df=6, P=0.64
Size (mm)†
<10 30 (23.4) 186 (25.3) 24 (31.6) 171 (31.0)
10›19 51 (39.8) 299 (40.7) 35 (46.1) 234 (42.4)
20›29 31 (24.2) 140 (19.1) 13 (17.1) 96 (17.4)
30›39 8 (6.3) 58 (7.9) 2 (2.6) 31 (5.6)
40›49 5 (3.9) 30 (4.1) 1 (1.3) 11 (2.0)
>50 3 (2.3) 21 (2.8) 1 (1.3) 9 (1.6)
Missing data 12 24 8 18
Significance ÷2=0.01, df trend=1, P=0.92 ÷2=0.63, df trend=1, P=0.43
No of nodes†
None 96 (77.4) 437 (66.7) 58 (84.1) 354 (73.8)
<4 20 (16.1) 150 (22.9) 8 (11.6) 95 (19.8)
>4 8 (6.5) 68 (10.4) 3 (4.3) 31 (6.5)
Missing data 16 103 15 90
Significance ÷2=5.09, df trend=1, P=0.03 ÷2=2.74, df trend=1, P=0.1
Nottingham prognostic index‡
Low 65 (62.5) 307 (57.5) 44 (74.6) 264 (67.2)
Medium 29 (27.9) 180 (33.7) 13 (22.0) 109 (27.7)
High 10 (9.6) 47 (8.8) 2 (3.4) 20 (5.1)
Significance ÷2=1.34, P=0.51 ÷2=1.33, P=0.51
Insufficient information 50 280 29 194
*Includes tubular and mucoid tumours.
†Excludes ductal carcinoma in situ and missing grades.
‡Nottingham prognostic index (in which a low score indicates a better prognosis than a high score) does not apply to cases of ductal carcinoma in situ.
Endpiece
Religion
That very large part of mankind who have religion
enough to make them uneasy when they do wrong,
and not religion enough to keep them from doing
wrong.
Lord Macauley
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